The CABANA-HF trial is an international, multicenter, randomized trial evaluating catheter ablation versus guideline-directed medical therapy for atrial fibrillation in HFpEF.
About the Trial
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) together affect approximately 1.2 million patients in the United States. These patients face a 25–60% event rate at five years, yet no dedicated randomized controlled trial has evaluated catheter ablation of AF in this high-risk population—until now.
All participants receive contemporary guideline-directed medical therapy including SGLT2 inhibitors, MRAs, ARNI, and GLP1-RA alongside rhythm-control strategies.
With over 120 sites across 12 countries, CABANA-HF will generate evidence applicable to diverse patient populations worldwide.
CABANA-HF is funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Whether you are a clinician, researcher, or potential participant, learn how you can contribute to advancing care for HFpEF.
Get Involved